ERA4TB accelerates the development of new treatment regimens for tuberculosis.

Effects of the COVID-19 on the fight against tuberculosis

The general public is well aware of the tragic impact of the COVID-19 on the community in terms of lives, disruption of livelihoods and social distress. Far less obvious are the indirect effects that the outbreak exert on other major diseases of global incidence like tuberculosis. To contain the spread of the COVID-19, most countries have imposed strict lockdown measures that, however necessary, are negatively affecting the programs to eradicate tuberculosis at global level by hindering TB diagnosis, notifications and likely shortening the provision of drugs against the infection.

The Stop-TB Partnership has been working on a series of models to estimate the effect of the COVID-19 outbreak on the progress of TB at global scale. These models focus on three countries with a high burden of TB and distinct social settings that constitute paradigmatic cases within the spectrum of countries in which TB has a high incidence. In the worst-case scenario, the modelers estimated that a 3-month lockdown followed by a 10-month period to return to normality could lead to an additional 6.3 million cases of TB between 2020 and 2025, and an additional 1.4 million TB deaths during this time at global level. With these figures, the gains made in the fight against TB in the last five to eight years could be lost out. The study stresses that recovering the progress made in the last years will only be possible through increasing the efforts and investments in TB.

ERA4TB stands in solidarity with the additional difficulties that the present situation imposes on patients and professionals involved in treating TB. ERA4TB is committed with the development of new drugs of easy administration and effectivity against resistant strains, the consortium hopes to help mitigate the consequences of the COVID-19 outbreak on the battle against TB.

ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for tuberculosis.

Objectives

The main objective of ERA4TB is to create a European open platform to accelerate the development of new regimens for the treatment of tuberculosis.

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Structure

The ERA4TB platform is based on a progression pipeline that can cater for a variety of molecules at different stages of development.

News

Follow our articles and ERA4TB news

Event

Project Update – 3th Consortium Meeting

The third ERA4TB Consortium Meeting took place last June 9th and 10th with the participation…
Press

COVID-19 highlights urgent need to reboot global effort to end tuberculosis [Press Release – WHO]

An estimated 1.4 million fewer people received care for tuberculosis (TB) in 2020 than in…
Event

Consortium Meeting

On January 26th and 27th the second Consortium Meeting took place online to share the…

Twitter

Follow us and be the first
to know what we do

Our 2nd Annual Meeting is about to start and we are so excited to see the many partners from the 8 running projects connecting together for a half-day of learnings, best practice exchanges & networking! #AMR 🧬🧫🤝

More details about the programme ⬇️
https://amr-accelerator.eu/wp-content/uploads/2021/09/Cross-Accelerator-Event_2021_A4_Clear-version_Public-version.pdf

@borobia_am @IMI_ERA4TB @IdipazScience Gran trabajo de todo el equipo de coordinación del WP7 de @IMI_ERA4TB para conseguir que dos nuevas moléculas para el tratamiento de la #tuberculosis estén ya en experimentación clínica @antoniojcarcas @borobia_am. Ahora vamos a por la tercera molécula 💪🏻

@IMI_ERA4TB está llamado a transformar radicalmente la forma en que se desarrolla la terapia para el tratamiento de la tuberculosis. Investigadores del @IdipazScience #HospitalLaPaz coordinan el desarrollo de los ensayos First-In-Human.
👉https://mailchi.mp/idipaz.es/investigadores-del-idipaz-lideran-un-gran-proyecto-internacional-para-desarrollar-nuevos-tratamientos-contra-la-tuberculosis

Our @NICEComms portfolio of @IMI_JU and #Horizon2020 @EuropeanCommiss funded projects covers a number of methodological and therapeutic-area specific projects:
@IMI_EHDEN @HarmonynetEU @IMI2_NEURONET @HTx_H2020 @IMI_ERA4TB and @ValueDx

Looking forward to expanding it!

Load More...

Know how accelerate the development of new treatment regimens for tuberculosis, discover our project

The Project